Inhibitor Therapeutics (INTI) 10% Owner Ronald E. Osman Receives Award

What Happened

• Ronald E. Osman, reported as a 10% owner of Inhibitor Therapeutics (INTI), was granted 50,000 restricted shares on May 4, 2026. The shares were issued as compensation at $0.00 per share (i.e., no cash purchase price reported).
• The award is described as restricted common stock issued pursuant to the Issuer's 2014 Equity Incentive Plan and is subject to shareholder approval.

Key Details

• Transaction date: May 4, 2026; reported on Form 4 filed Aug 4, 2026 (late filing).
• Security: Common stock; Amount: 50,000 shares; Price reported: $0.00 (award/grant).
• Beneficial ownership per filing: the footnotes state 100,000 shares are owned directly by Mr. Osman, plus additional shares held by The Ronald E. Osman Trust III (Mr. Osman is sole trustee).
• Footnotes: F1 = restricted shares issued as compensation under the 2014 Equity Incentive Plan, subject to shareholder approval. F2 = clarifies split between shares owned by Mr. Osman and those held by his trust.
• Timeliness: The Form 4 was filed roughly three months after the transaction; late reporting reduces near-term transparency but does not by itself imply trading intent.

Context

• This is an award/grant (compensation) rather than a market purchase or sale — awards are common for incentivizing insiders and do not directly signal a buy/sell market view.
• As a 10% owner (not listed here as an executive title), Mr. Osman is a significant shareholder; holdings include both direct and trust-held shares.